Breaking News Instant updates and real-time market news.

PFPT

Proofpoint

$71.00

-6.62 (-8.53%)

, ETFC

E-Trade

$34.62

0.9 (2.67%)

17:24
04/20/17
04/20
17:24
04/20/17
17:24

On The Fly: After Hours Movers

UP AFTER EARNINGS: Proofpoint (PFPT), up 8.1%... E-Trade (ETFC), up 2.7%... Visa (V), up 2.6%... Hawaiian Holdings (HA), up 2.4%... Maxim Integrated (MXIM), up 1.2%. ALSO HIGHER: VBL Therapeutics (VBLT), up 16.4% after it announced a "positive" DSMC review in its Phase 3 GLOBE trial investigating VB-111 in recurrent gioblastoma... Navios Maritime Partners (NMM), up 5.5% after it agreed to acquire the entire container fleet of Rickmers Maritime for about $113M... Antares Pharma (ATRS), up 1.8% after the stock was initiated with a Strong Buy at Raymond James. DOWN AFTER EARNINGS: Electronics for Imaging (EFII), down 12.1%... Mattel (MAT), down 6.2%... Manhattan Associates (MANH), down 6.1%... NCR Corp. (NCR), down 2.5%. ALSO LOWER: Adamis Pharmaceuticals (ADMP), down 12.5% after it filed to sell common stock... Gramercy Property Trust (GPT), down 3.5% after it filed to sell 9M shares of common stock... Hasbro (HAS), down 1.4% after Mattel reported weaker-than-expected quarterly results, citing a "retail inventory overhang" coming out of the holiday period.

PFPT

Proofpoint

$71.00

-6.62 (-8.53%)

ETFC

E-Trade

$34.62

0.9 (2.67%)

V

Visa

$91.15

1.4 (1.56%)

HA

Hawaiian Holdings

$51.90

1.4 (2.77%)

MXIM

Maxim Integrated

$45.45

0.86 (1.93%)

VBLT

VBL Therapeutics

NMM

Navios Maritime Partners

$1.99

-0.01 (-0.50%)

ATRS

Antares Pharma

$2.76

0.04 (1.47%)

EFII

Electronics for Imaging

$50.85

0.61 (1.21%)

MAT

Mattel

$25.21

0.1 (0.40%)

MANH

Manhattan Associates

$50.58

0.02 (0.04%)

NCR

NCR Corp.

$44.64

1.21 (2.79%)

ADMP

Adamis Pharmaceuticals

$4.40

-0.1 (-2.22%)

GPT

Gramercy Property Trust

$28.50

0.28 (0.99%)

HAS

Hasbro

$96.01

0.5 (0.52%)

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 24

    Apr

  • 27

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 18

    May

  • 18

    May

  • 22

    Jun

  • 20

    Oct

  • 21

    Apr

  • 21

    Apr

PFPT Proofpoint
$71.00

-6.62 (-8.53%)

04/19/17
DADA
04/19/17
UPGRADE
Target $90
DADA
Buy
Proofpoint upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Jack Andrews upgraded Proofpoint to Buy and raised his price target for the shares to $90 from $83. The relative underperformance of the shares since October has created an attractive entry point, Andrews tells investors in a research note. The analyst notes his channel checks have consistently revealed that email and social engineering threats are considered the biggest security challenges. He sees near-term catalysts driving further momentum at Proofpoint.
04/20/17
BARD
04/20/17
DOWNGRADE
BARD
Neutral
Proofpoint downgraded to Neutral from Outperform at Baird
04/20/17
BARD
04/20/17
DOWNGRADE
Target $77
BARD
Neutral
Proofpoint downgraded to Neutral at Baird
As reported previously, Baird analyst Jayson Noland downgraded Proofpoint to Neutral from Outperform citing concerns about sales execution that have accelerated lately. The analyst sees downside risk to earnings, though he said the company is still best-in-class in network security. Noland lowered his price target to $77 from $92 on Proofpoint shares.
04/12/17
SPHN
04/12/17
NO CHANGE
Target $95
SPHN
Overweight
Proofpoint recent pullback offers buying opportunity, says Stephens
Stephens analyst Jonathan Ruykhaver says his Q1 checks on underlying activity have been consistently positive, and thinks the momentum Proofpoint has experienced over the last quarters around competitive wins and increasing sales of new Targeted Attack Preventon continues and can drive Q1 upside. The analyst expects "strong Q1 results" and says the recent pullback offers a buying opportunity. He reiterates an Overweight rating and $95 price target on the shares.
ETFC E-Trade
$34.62

0.9 (2.67%)

03/02/17
SDLR
03/02/17
DOWNGRADE
SDLR
Hold
E-Trade downgraded to Hold from Buy at Sandler O'Neill
03/13/17
03/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BofA Merrill Lynch analyst Kevin Fischbeck assumed coverage of Cigna (CI) with a Buy rating and $175 price target. The company's core business continues to improve, which will drive above average earnings growth in 2017, the analyst contends. 2. Canaccord Genuity analyst Richard Close started Health Insurance Innovations (HIIQ) with a Buy rating and $28 price target. Deregulation under the Trump administration provides a favorable growth outlook for the company's insurance sales, the analyst said. 3. Jefferies analyst Philippe Houchois started Ferrari (RACE) with a Buy rating and $74 price target. 4. Baird analyst Mircea Dobre started John Bean Technologies (JBT) with an Outperform rating and $101 price target, while Wells Fargo analyst Allison Poliniak-Cusic started John Bean Technologies with an Outperform rating and $100-$102 price target range. 5. UBS analyst Brennan Hawken started E-Trade Financial (ETFC) with a Buy rating and $43 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/28/17
RHCO
02/28/17
NO CHANGE
RHCO
Online brokers defended at SunTrust
SunTrust reiterate our Buy ratings on Charles Schwab (SCHW), E-Trade (ETFC), and TD Ameritrade (AMTD) shares following Fidelity Investments' announcement of a cut of its base commission rate to $4.95 per trade. The firm's analyst believes the ultimate impact will be less than headlines suggest due to high switching costs, high volume traders already pay lower rates, and increased asset-based revenue is the primary driver of growth, not commissions.
03/13/17
UBSW
03/13/17
INITIATION
Target $43
UBSW
Buy
E-Trade initiated with a Buy at UBS
UBS analyst Brennan Hawken started E-Trade Financial with a Buy rating and $43 price target. New management's plan to improve operating metrics or seek a buyer for the franchise should help limit the stock downside, Hawken tells investors in a research note.
V Visa
$91.15

1.4 (1.56%)

04/06/17
CHLM
04/06/17
NO CHANGE
Target $52
CHLM
Buy
Extended partnership with Visa will increase PayPal relevance, says Craig-Hallum
Craig-Hallum analyst Brad Berning notes that PayPal (PYPL) and Visa (V) have extended their relationship to the Asia Pacific Region, duplicating the U.S. partnership announcement last year as they work to expand globally. While spending in-store POS is likely to be largely a pass through revenue event for PayPal, it will increase its relevance, which the analyst expects to increase overall adoption and engagement over time. Berning reiterates a Buy rating and $52 price target on PayPal's shares.
02/15/17
02/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kraft Heinz (KHC) and ConAgra Brands (CAG) were initiated with Buy ratings at Deutsche Bank. The firm also initiated Campbell Soup (CPB), J.M. Smucker (SJM) General Mills (GIS), Hershey (HSY), Kellogg (K) and Mondelez (MDLZ) with a Hold, as well as Pinnacle Foods (PF), Hostess Brands (TWNK) and Snyder's Lance (LNCE) with a Buy. 2. MasterCard (MA) and Visa (V) initiated with Buy ratings at Loop Capital by analyst Joseph Vafi. 3. Bioverativ (BIVV) initiated with an Outperform rating and $56 price target at Leerink by analyst Jason Gerberry. 4. Encana (ECA) initiated with an Overweight at JPMorgan. The firm also reinstated Cheniere Energy (LNG) and Cheniere Energy Partners LP (CQH) with Overweight ratings. 5. Blueprint Medicines (BPMC) initiated with an Overweight at Morgan Stanley by analyst Andrew Berens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here
04/13/17
LEHM
04/13/17
NO CHANGE
Target $103
LEHM
Overweight
Barclays still 'strongly' recommends shares of Visa
Barclays analyst Darrin Peller believes the outperformance of Visa shares is likely sustainable as currency, gas price and Russia headwinds ease. The analyst continues to "strongly recommend" the stock throughout the first half of 2017. Peller believes Visa could post upside in Q2 and keeps an Overweight rating on the name with a $103 price target.
04/19/17
OPCO
04/19/17
NO CHANGE
OPCO
Oppenheimer bullish on Visa, MasterCard ahead of results
Oppenheimer analyst Glenn Greene reiterates Outperform ratings for MasterCard (MA) and Visa (V) and $120 and $95 price targets, respectively, heading into results. The analyst is encouraged by "solid" January intra-quarter volume growth, improving gas price trends, strong retail sales growth, and broadly positive card issuer trends. Further, Greene continues to believe that MasterCard and Visa are attractive at current levels, given their defensible market positions and strong long-term prospects. Nonetheless, he prefers Visa relative to MasterCard at present given the continuing U.S. volume boost from the Costco (COST)/USAA wins and JPMorgan Chase (JPM) Sapphire Reserve momentum, apparent conservative guidance, and Visa Europe accretion benefits.
HA Hawaiian Holdings
$51.90

1.4 (2.77%)

02/09/17
WOLF
02/09/17
UPGRADE
WOLF
Outperform
Hawaiian Holdings upgraded to Outperform from Peer Perform at Wolfe Research
02/09/17
02/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIA, VIAB) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying the company's first quarter results prove its turnaround is "real and likely to continue." The strategic plan put in place by CEO Bakish makes sense, Ryvicker tells investors in a research note. The analyst raised his price target range for the shares to $48-$50 from $38-$40. 2. Micron (MU) upgraded to Buy from Underperform at BofA/Merrill. 3. Sanofi (SNY) upgraded to Buy from Neutral at Natixis. 4. Hawaiian Holdings (HA) upgraded to Outperform from Peer Perform at Wolfe Research. 5. Baker Hughes (BHI) upgraded to Positive from Neutral at Susquehanna with analyst Charles Minervino citing the selloff in shares and its upside opportunity associated with a US spending upcycle, synergies from its joint-venture with General Electric (GE), and the growth opportunities that could develop from a partnership with a diversified global oilfield services company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
11/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cisco (CSCO) coverage resumed with a Hold at Stifel. 2. UPS (UPS) was initiated with an Outperform at BMO Capital while the firm initiated FedEx (FDX) with a Market Perform. 3. Synchrony (SYF) was initiated with an Overweight at Stephens. The firm also initiated American Express (AXP) and Discover (DFS) with an Underweight. 4. American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and Allegiant Travel (ALGT) were initiated with a Buy at Citi while the firm initiated JetBlue (JBLU), United Continental (UAL), Alaska Air (ALK), and Hawaiian Holdings (HA) with a Neutral. 5. Juniper (JNPR) coverage resumed at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/17
BOFA
01/10/17
DOWNGRADE
BOFA
Underperform
Hawaiian Holdings downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Andrew Didora downgraded Hawaiian Holdings citing peak valuation and maintained its $55 price target.
MXIM Maxim Integrated
$45.45

0.86 (1.93%)

03/30/17
MACQ
03/30/17
INITIATION
Target $52
MACQ
Outperform
Maxim Integrated initiated with an Outperform at Macquarie
Macquarie analyst Srini Pajjuri initiated Maxim with an Outperform and a $52 price target.
04/13/17
LOOP
04/13/17
NO CHANGE
Target $51
LOOP
Buy
Loop Capital expects Maxim Integrated to beat Street Q3 estimates
Loop Capital analyst Betsy Van Hees expects Maxim Integrated (MXIM) to report Q3 results above Street estimates of 52c/$575M, and increased her earnings estimate to $54c on revenue of $585M. The analyst said an upbeat Silicon Valley Bus Tour and industry checks suggest healthy demand in the automotive, communications & data center, and industrial end markets will drive the strength. Van Hees expects tailwinds to continue in Q4 and reiterates her Buy rating and increased her price target to $51 from $50.
01/27/17
BOFA
01/27/17
UPGRADE
Target $51
BOFA
Buy
Maxim Integrated upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Vivek Arya upgraded Maxim to Buy and raised its price target to $51 from $43 saying Q2 results addressed prior concerns regarding high exposure to Samsung and sluggish revenues. The analyst said Samsung exposure will be below 10% going forward, while sales should accelerate to 4-5% year-over-year in 2017/18. He said the balance sheet is solid, free cash flow is strong, and the turnaround will be led by growth in autos, industrial, and networking.
01/27/17
DBAB
01/27/17
NO CHANGE
Target $50
DBAB
Buy
Maxim Integrated price target raised to $50 from $45 at Deutsche Bank
Deutsche Bank analyst Ross Seymore raised his price target for Maxim Integrated to $50 saying the company's "solid" Q2 results showed core strength in Auto. The analyst reiterates a Buy rating on the shares.
VBLT VBL Therapeutics

06/07/16
CHDN
06/07/16
NO CHANGE
Target $20
CHDN
Buy
Chardan continues to see significant upside for VBL Therapeutics
Chardan continues to see significant upside for VBL Therapeutics shares given VB-111 has convincing efficacy signals for rGBM, ovarian, and thyroid cancer types, an immune-therapeutic effect for VB-111 has been supported in the rGBM and ovarian trials, and the product has orphan drug designations in the US and Euripe for rGBM, Fast Track designation by the FDA for rGBM, and a special protocol assessment by the FDA for the Phase III program in rGBM. Chardan rates VBL Therapeutics a Buy with a $20 price target on shares.
06/28/16
HCWC
06/28/16
INITIATION
Target $11
HCWC
Buy
VBL Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started VBL Therapeutics with a Buy rating and $11 price target.
11/29/16
ROTH
11/29/16
NO CHANGE
Target $17
ROTH
Buy
VBL Therapeutics thyroid study points in right direction, says Roth Capital
Roth Capital analyst Joseph Pantginis notes that VBL Therapeutics has announced positive follow-up overall survival data from the Phase 2 thyroid cancer study with VB-111. The analyst believes VB-111 represents a "strong potential option" for patients with recurrent glioblastoma and looks forward to clinical progress in the Phase 3 rGBM study. Pantginis projects upside from future clinical updates, expansion opportunities for new indications as well as partnership potential for VB-111. He reiterates a Buy rating and $17 price target on the shares.
11/29/16
ROTH
11/29/16
NO CHANGE
ROTH
VBL Therapeutics mentioned positively at Roth Capital
NMM Navios Maritime Partners
$1.99

-0.01 (-0.50%)

ATRS Antares Pharma
$2.76

0.04 (1.47%)

04/20/17
RAJA
04/20/17
INITIATION
Target $4.3
RAJA
Strong Buy
Antares Pharma initiated with a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur initiated Antares Pharma with a Strong Buy and a $4.30 price target telling investors its business model diversity provides management with multiple value creation levers by playing in the generics arena targeting the $70B U.S. auto-injector and pre-filled syringe market, serving as life-cycle extension partner for branded assets facing end of life crisis or capturing full economic value of self-developed proprietary drugs.
03/31/17
JEFF
03/31/17
NO CHANGE
JEFF
Jefferies doubles Antares price target to $6 from $3
Jefferies analyst Anthony Petrone doubled this price target on shares of Antares Pharma to $6 from $3. The stock in early trading is up 7c to $2.81. In a research note today to investors, Petrone said his thesis on the company continues to be that its pipeline is well positioned to see a "succession of positive catalysts" over the next 24 months. Five pipeline products through 2019 collectively address $8B in new market opportunities, Petrone contends. He sees potential share upside to $15 with successful product launches "overtime." The FDA action date for Quickshot Testosterone, Antares' sub-Q testosterone replacement therapy, is October 20, 2017. Based on a "strong" clinical profile, the analyst assumes QST can capture 50% from existing brands or 15% of the total market.
EFII Electronics for Imaging
$50.85

0.61 (1.21%)

10/25/16
SBSH
10/25/16
NO CHANGE
Target $52
SBSH
Buy
Electronics for Imaging selloff brings buying opportunity, says Citi
Citi analyst Jim Suva sees the post-earnings selloff in shares of Electronics for Imaging (EFII) as a "rare opportunity." The challenges with the company's Fiery product is directly tied to the separation occurring at Xerox (XRX) which is on track to occur the end of this year, Suva tells investors in a post-earnings research note. He calls Electronics for Imaging his top small cap stock pick. The analyst lowered his price target for the shares to $52 from $54 and keeps a Buy rating on the name.
10/25/16
BMUR
10/25/16
NO CHANGE
Target $60
BMUR
Buy
Electronics for Imaging core thesis remains intact, says Brean Capital
Brean Capital analyst Ananda Baruah noted Electronics for Imaging reported mixed Q3 results but said the core thesis remains intact. Baruah said the core inkjet business grew 17% organically but the Fiery softness was a bother given recent stock optics. The analyst is not sure how the stock will react but recommends buying on any weakness. Baruah reiterated a Buy rating and $60 price target on Electronics for Imaging shares.
09/27/16
NEED
09/27/16
INITIATION
Target $58
NEED
Buy
Electronics for Imaging initiated with a Buy at Needham
Needham analyst James Ricchiuti initiated Electronics for Imaging with a Buy and a $58 price target. The analyst said Electronics for Imaging has a long and successful track record of disrupting the analog printing market and sees accelerating organic growth in 2017 and 2018, benefiting from improving conditions in its core markets and growing momentum in new areas, notably the corrugated packaging printing market.
12/01/16
WBLR
12/01/16
NO CHANGE
WBLR
General Electric, Crane among top industrial picks at William Blair
William Blair named GE (GE), Crane (CR), HD Supply (HDS), Allison Transmission (ALSN), Electronics for Imaging (EFII), and Ritchie Bros. (RBA) as its top industrial picks for 2017. It identified GE as its top multi-industry pick, HD Supply as its top distributor pick, Allison as its top capital goods pick, Crane as its top Engineered Equipment, Engineering & Construction pick, Electronics for Imaging as its top Filtration & Water Management; Industrial Technology pick, and Ritchie Bros as its top transportation and logistics pick.
MAT Mattel
$25.21

0.1 (0.40%)

02/13/17
02/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Air Products (APD) reinstated with an Overweight at Barclays. 2. Hasbro (HAS) was initiated with a Buy at Goldman, while Mattel (MAT) was initiated with a Neutral. 3. Jagged Peak Energy (JAG) initiated with a Positive at Susquehanna. 4. Kimbell Royalty Partners (KRP) initiated with a Buy at Wunderlich. 5. HollyFrontier (HFC) reinstated with a Sell at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/17
GSCO
02/13/17
INITIATION
Target $27
GSCO
Neutral
Mattel initiated with a Neutral at Goldman
Goldman analyst Michael Ng initiated Mattel with a Neutral and a $27 price target. The analyst said Mattel is undergoing a turnaround in several of its core brands but consensus estimates are already looking for a meaningful recovery, creating increased risk.
02/08/17
PIPR
02/08/17
NO CHANGE
PIPR
Piper discusses resurfacing of Hasbro, Mattel deal speculation
Piper Jaffray analyst Stephanie Wissink points out that over her firm's 15 years of coverage, speculation of a merger between Hasbro (HAS) and Mattel (MAT) has surfaced several times. Hasbro's strong Q4 earnings report and share rally, in contrast with Mattel's negative Q4 preannouncement and pullback, has reignited the conjecture, Wissink tells investors in a research note. Economically a merger would create value, but a combination of the number two and three toy companies "would require significant evaluation from anti-trust authorities," the analyst writes. She believes a deal is possible if the Federal Trade Commission widens the boundaries around "youth entertainment & play," say to include video games, digital games and media. Hasbro closed yesterday up 67c to $94.98 while Mattel, after rallying in early trading, closed down 4c to $25.88. Wissink adds that she can find upwards of $500M of merger synergies if the two companies were to combine.
03/14/17
UBSW
03/14/17
NO CHANGE
UBSW
Buy
UBS discusses scenarios for hypothetical Mattel/Hasbro merger
UBS analyst Arpine Kocharyan noted market speculation about a potential merger of Hasbro (HAS) and Mattel (MAT). While admitting she has no view on the possibility of a deal happening, she does say there is large equity valuation gap between the two, with Mattel pricing in a potential dividend cut, and expressed her view that industry consolidation could pick up in 2017. Koocharyan maintains her Buy rating on Mattel and Neutral rating on Hasbro shares.
MANH Manhattan Associates
$50.58

0.02 (0.04%)

01/09/17
RAJA
01/09/17
DOWNGRADE
RAJA
Market Perform
Manhattan Associates downgraded to Market Perform at Raymond James
01/09/17
01/09/17
DOWNGRADE

Market Perform
Manhattan Associates downgraded on headwinds at Raymond James
As previously reported, Raymond James downgraded Manhattan Associates to Market Perform from Outperform. Analyst Terry Tillman said checks indicate solid software activity but pockets of weakness in the retail segment and some large deal potential deferral activity that could impact both software license and professional services revenue and linger into 2017. Furthermore, recent negative headlines out of big box retailers and others too heavily geared towards brick and mortar while lacking an adequate omni-channel strategy, could potentially impact sales for the company, the analyst wrote.
02/01/17
BNCH
02/01/17
NO CHANGE
Target $65
BNCH
Buy
Manhattan Associates price target lowered to $65 from $71 at Benchmark
Benchmark analyst Mark Schappel acknowledges he considered stepping aside with a downgrade of Manhattan Associates after the company's earnings report and "meaningfully lower" revenue outlook for 2017, but he believes the services business will bottom in Q1, allowing for a resumption of growth in the second half of the year if management executes. He keeps a Buy rating on Manhattan Associates shares, but cut his price target to $65 from $71 on the stock.
01/26/17
BMUR
01/26/17
NO CHANGE
Target $75
BMUR
Buy
Manhattan Associates services weakness likely to linger, says Brean Capital
Brean Capital analyst Yun Kim said his most recent channel checks for Manhattan Associates indicate services weakness remains and may linger. He said the checks also indicate the issues behind the weakness are temporary and not reflective of any decline in fundamentals. Kim believes the risk/reward at current valuation levels favor the long-term opportunity around the Omni-channel secular trend, which should offset the risks related to the current weakness. Kim reiterated his Buy rating and $75 price target on Manhattan Associates shares.
NCR NCR Corp.
$44.64

1.21 (2.79%)

01/23/17
RAJA
01/23/17
NO CHANGE
RAJA
Outperform
Q2 higher after Raymond James uncovers new Tier 1 client
Raymond James analyst Terry Tillman said his firm's channel checks indicate Q2 Holdings (QTWO) beat out Fiserv (FISV), FIS (FIS) and NCR Corp. (NCR) and signed new a new Tier 1 digital banking customer in the Northeast with over $12B in deposits. The rollout should be completed by mid-2017, Tillman told investors in a pre-open research note. He believes Q2 has continued to see bookings improve from Q2 and Q3 levels and that 30%-plus revenue growth remains achievable. The analyst has an Outperform rating on the shares. Q2 is up 35c to $31.60 in early trading.
04/13/17
BNCH
04/13/17
INITIATION
Target $55
BNCH
Buy
NCR Corp. initiated with a Buy at Benchmark
Benchmark analyst Daniel Kurnos initiated NCR Corp with a Buy and a $55 price target.
03/16/17
OPCO
03/16/17
UPGRADE
Target $51
OPCO
Outperform
NCR Corp. upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Ian Zaffino upgraded NCR Corp. to Outperform citing the 10% pullback in the shares since March 10. Blackstone's reduced stake does not portend weakening fundamentals, the analyst contends. He has a $51 price target for the shares.
04/13/17
04/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Auris Medical (EARS) initiated with a Buy at Roth Capital. 2. NCR Corp. (NCR) initiated with a Buy at Benchmark. 3. Guaranty Bancorp (GBNK) initiated with an Overweight at Piper Jaffray. 4. Six Flags (SIX) and SeaWorld (SEAS) were initiated with a Buy at SunTrust, while Cedar Fair (FUN) was initiated with a Hold. 5. Stericycle (SRCL) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ADMP Adamis Pharmaceuticals
$4.40

-0.1 (-2.22%)

12/20/16
RILY
12/20/16
INITIATION
Target $5
RILY
Buy
Adamis Pharmaceuticals initiated with a Buy at B. Riley
B. Riley analyst Greg Chodaczek started Adamis Pharmaceuticals with a Buy rating and $5 price target. The company has three respiratory products in its development pipeline, representing a $20B opportunity, the analyst contends.
01/24/17
MAXM
01/24/17
NO CHANGE
Target $10
MAXM
Buy
Adamis undervalued if able to take just 10% of EpiPen market, says Maxim
After privately-held Kaleo announced a "complex pricing strategy" for their EpiPen-like device, Auvi-Q, which is returning to the market, Maxim analyst Jason Kolbert said he views Adamis' (ADMP) PFS to be a better, more user friendly product than Mylan's (MYL) EpiPen, Impax Labs' (IPXL) Adrenaclick and Kaleo's AuviQ. If Adamis can acquire just 10% market share, which he believes is at the low end, the shares are undervalued, Kolbert tells investors. He keeps a Buy rating and $10 price target on Adamis shares.
12/19/16
MAXM
12/19/16
NO CHANGE
Target $10
MAXM
Buy
Adamis resubmission sets up mid-year PDUFA for generic EpiPen, says Maxim
Maxim analyst Jason Kolbert said Adamis Pharmaceuticals' (ADMP) resubmission of its New Drug Application for its epinephrine pre-filled syringe, a generic version of Mylan's (MYL) EpiPen, addresses all the issues in the FDA Complete Response Letter and triggers a 30 day review to "accept" the filing, which should be followed by a six month PDUFA date and approval by June of next year, he believes. Adamis' version is more user friendly, design wise, than Mylan's generic and the market opportunity is large, said Kolbert, who thinks that this can become a significant product for the company "even with just moderate market share assumptions." He keeps a Buy rating and $10 price target on Adamis, which he sees as "poised for a breakout" in 2017.
GPT Gramercy Property Trust
$28.50

0.28 (0.99%)

01/09/17
JMPS
01/09/17
DOWNGRADE
JMPS
Market Perform
Gramercy Property Trust downgraded to Market Perform at JMP Securities
06/28/16
MUFG
06/28/16
INITIATION
Target $10.5
MUFG
Overweight
Gramercy Property Trust initiated with an Overweight at Mitsubishi UFJ
Mitsubishi UFJ analyst Karin Ford started Gramercy Property Trust with an Overweight rating and $10.50 price target.
12/05/16
BOFA
12/05/16
DOWNGRADE
BOFA
Neutral
Gramercy Property Trust downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst James Feldman downgraded Gramercy Property Trust to Neutral due to the rise in the cost of capital and limited upside from accelerating GDP growth given long lease terms of triple nets.
11/02/16
11/02/16
NO CHANGE

Gramercy Property Trust appoints Nicholas Pell as Chief Investment Officer
Gramercy Property Trust appointed Nicholas L. Pell as Chief Investment Officer. Previously, Pell was a Managing Director with Gramercy. His appointment is effective immediately.
HAS Hasbro
$96.01

0.5 (0.52%)

04/04/17
04/04/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Neutral due to valuation at BTIG. 2. HP Enterprise (HPE) initiated with a Hold at Berenberg. 3. Hasbro (HAS) initiated with a Neutral at B. Riley. 4. Lionsgate (LGF.A, LGF.B) initiated with a Buy at Canaccord. 5. Vistra Energy (VSTE) initiated with a Peer Perform at Wolfe Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/17
RILY
04/04/17
INITIATION
Target $111
RILY
Neutral
Hasbro initiated with a Neutral at B. Riley
B. Riley analyst Linda Bolton Weiser started Hasbro with a Neutral rating and $111 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.